Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers : vimarsana.com

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.



The...

Related Keywords

, Kishor Bhatia , Linkedin , Securities Exchange , Nasdaq , Bielefeld University , Lantern Pharma Inc , Exchange Commission On , Lantern Pharma , Business Wire , Chief Scientific Officer , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission , Markets ,